anti-CD19 CAR-T therapy / Wuhan Bio–Raid - LARVOL DELTA

Effect of signal peptide optimized by site-directed mutagenesis on the function of chimeric antigen receptor T cells (PubMed, Sheng Wu Gong Cheng Xue Bao) - "This study aimed to optimize the SP sequence by site-directed mutagenesis and investigate its impact on the killing function of CD19-CAR-T...In summary, this study revealed that increasing the N-terminal positive charge of the signal peptide can improve the expression efficiency of CAR and promote the killing of CD19+ target cells. These findings provide a scientific basis the optimization and clinical application of CAR structure."

CAR T-Cell Therapy • IO biomarker • Journal • Oncology • IFNG • TNFA

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. (PubMed, Front Immunol) - "The median doses of CD22 and CD19 CAR T cell infusions were 4.1 × 10/kg and 4.0 × 10/kg, respectively. Both the estimated 1-year progression-free and overall survival rates were 55.6%. Our preliminary results indicated that salvage therapy with CD19/CD22 CAR T cell infusion alone and that in combination with ASCT are effective in treating some adult patients with r/r Burkitt lymphoma."

Journal • Bone Marrow Transplantation • Burkitt Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Oncology • Transplantation • CD19 • CD22